Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Jean-Charles Soria

51-100 of 558 results

View this query on the Wikidata Query Service
Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

scientific article published on 16 February 2010
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer

scientific article published on 21 March 2012
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer

scientific article
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.

scientific article published on 21 January 2015
Involvement of aquaporins in colorectal carcinogenesis

scientific article published on October 2003
Dendritic cell-derived exosomes for cancer therapy

scientific article published on April 2016
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

scientific article published on 9 April 2018
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer

scientific article published on February 2016
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

scientific article published on 10 May 2017
Nonapoptotic role for Apaf-1 in the DNA damage checkpoint

scientific article published on November 2007
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

scientific article published on March 2007
Cisplatin resistance associated with PARP hyperactivation

scientific article
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth

scientific article
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

scientific article published on 01 October 2006
Cyclooxygenase-2 as a target for anticancer drug development

scientific article (publication date: July 2006)
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

scientific article published on 21 January 2013
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

scientific article published in September 2018
Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives

scientific article published in February 2005
Tumour stem cell-targeted treatment: elimination or differentiation

scientific article
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

scientific article published on January 8, 2016
Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer

article
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib

scientific article published on 13 July 2009
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

scientific article
Role of human aquaporin 5 in colorectal carcinogenesis

scientific article published on 26 June 2008
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

scientific article
Rationale for anti-OX40 cancer immunotherapy

scientific article
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

scientific article published on 11 January 2018
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res

scientific article
Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection

scientific article
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.

scientific article published on 15 June 2010
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors

scientific article
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

scientific article
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

scientific article published on 23 May 2010
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

scientific article published on 6 April 2015
Cyclophosphamide induces differentiation of Th17 cells in cancer patients

scientific article published on 09 December 2010
Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer

scientific article
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

scientific article published on 22 January 2015
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study

scientific article published on 17 March 2016
Hyperprogressive disease: recognizing a novel pattern to improve patient management

scientific article published on 01 December 2018
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

scientific article
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers

scientific article published on 01 November 2004
Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation

scientific article published on June 2008
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

scientific article published on 13 December 2018
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

scientific article published on 28 March 2011
Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer

scientific article published on December 1, 2001
Lung cancer mortality risk among breast cancer patients treated with anti-estrogens

scientific article published on 24 January 2011
Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carc

scientific article published on 01 July 2007
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

scientific article published on 17 January 2018
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

scientific article published on 14 February 2012
Prioritizing targets for precision cancer medicine

scientific article

Paulina is supported by:

About Paulina

Help